CLL breakthrough: stopping treatment may be possible for some patients

NCT ID NCT04419519

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undetectable cancer cells after venetoclax treatment can stop taking the drug and stay in remission for at least a year. Researchers will monitor 81 participants to see how many remain cancer-free without ongoing therapy. The goal is to reduce unnecessary drug exposure while maintaining disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (with or without anti-CD20 antibody)
What this could lead to: If successful, this could show that some CLL/SLL patients can take a break from treatment without the disease coming back quickly, reducing drug side effects and costs.
What could go wrong: This is a small Phase 2 study (81 people) and results may not apply to all patients. Some patients may relapse after stopping venetoclax, and the long-term safety of treatment interruption is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Memorial Sloan Kettering Basking Ridge (All protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All protocol activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, 10604, United States
University of Washington

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.